WuXi PharmaTech and OMT Announce OmniRat™ Antibody Collaboration
News Jan 17, 2013
WuXi PharmaTech and Open Monoclonal Technology, Inc. (OMT), have announced that they have entered into an agreement to use OMT’s OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi’s global customers.
This transaction advances WuXi’s goal of working with skilled partners to enhance the company’s platform of technologies and capabilities to serve its customers better.
The OmniRat™ technology generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology.
“OMT’s OmniRat™ technology allows WuXi to expand its service offerings in discovery of fully human antibodies,” said Edward Hu, Chief Operating Officer and Chief Financial Officer of WuXi PharmaTech.
Hu continued, “Providing discovery, development and manufacturing services for novel therapeutic antibodies represents an important new global business initiative for WuXi. We are investing heavily in building our capabilities and capacity in biologics services, which we expect to be a key driver of revenue growth for our company in the coming years.”
Dr. Roland Buelow, founder and CEO of OMT, continued, “The collaboration with WuXi further advances OMT’s efforts to deploy its human antibody platform globally. Under the collaboration, OMT can leverage WuXi’s expertise and capacity to create novel therapeutic candidates for its biopharmaceutical customers and apply OMT’s technology to an ever-broadening base of drug candidates.”
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017